title: Lebrikizumab for the treatment of asthma.
abstract: BACKGROUND
  In asthma, most commonly, 'conventional' anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain inflammation pathways and lebrikizumab an anti IL-13 molecule might represent a relevant example as a potential asthma therapy.
  
  
  METHODS
  Discussion of the rationale for the use of lebrikizumab in asthma. Analysis of the related preclinical and clinical data on lebrikizumab in asthma.
  
  
  CONCLUSIONS
  Lebrikizumab demonstrated efficacy in an asthma subset characterized by high serum periostin levels and by heavy eosinophilic inflammation. Phase III data are necessary in order to better position this therapy in asthma including as a potential personalized approach.
authors.affiliation: a Department of Surgery II-Palliative Care Nursing , University of Medicine and Pharmacy Gr.T.Popa Iasi , Iasi , Romania.
authors.forename: Sabina Antonela
authors.initials: SA
authors.lastname: Antoniu
mesh_terms: D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D015195:Drug Design; D006801:Humans; D018793:Interleukin-13 / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D018793:Interleukin-13; C561806:lebrikizumab
keywords: Asthma; IL-13; allergy; antibody; lebrikizumab; periostin